News Releases

 
News Releases
  Date Title and Summary View
May 5, 2009
Mountain View, CA - May 5, 2009 - ChemoCentryx, Inc., today announced that it has identified an orally bioavailable small molecule antagonist of the C5a receptor, CCX168, as a candidate for clinical development. The acceptance of the molecule as a development candidate triggered a $5.0 million milestone payment from the alliance wi...
Oct 15, 2008
Mountain View, CA - October 15, 2008 - ChemoCentryx, Inc., announced today that it has initiated a Phase I clinical trial of CCX025, the company's fourth investigational new drug and second orally administered compound that inhibits the chemokine receptor known as CCR9. Structurally distinct from Traficet-ENTM (CCX282-B;...
Oct 15, 2008
Mountain View, CA - October 15, 2008 - ChemoCentryx, Inc., announced today that it has initiated a Phase I clinical trial of CCX025, the company's fourth investigational new drug and second orally administered compound that inhibits the chemokine receptor known as CCR9. Structurally distinct from Traficet-ENTM (CCX282-B;...
Jun 12, 2008
Mountain View, CA - June 12, 2008 - ChemoCentryx, Inc., today announced the completion of enrollment of 436 patients in the company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial), a Phase II/III clinical trial of Traficet-ENTM (CCX282-B) in patients with moderate-tosevere Crohn'...
Jun 12, 2008
Mountain View, CA - June 12, 2008 - ChemoCentryx, Inc., today announced the completion of enrollment of 436 patients in the company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial), a Phase II/III clinical trial of Traficet-ENTM (CCX282-B) in patients with moderate-tosevere Crohn'...
May 13, 2008
Mountain View, CA - May 13, 2008 - ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX354, an orally-available, novel small molecule compound designed to specifically target the CCR1 chemokine receptor which is associated with inflammatory diseases such as rheumatoid arthritis. With the dosing of t...
Jan 17, 2008
Mountain View, CA - January 17, 2008 - ChemoCentryx, Inc. today announced the appointment of Edward E. Penhoet, Ph.D., to the company's Board of Directors. Dr. Penhoet is recognized for his 25 years of leadership and contributions in the public and private sectors of the life sciences industry, including as co-founder and Chief Exe...
Sep 26, 2007
Mountain View, CA - September 26, 2007 - ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics that target the chemokine system, today announced the publication of data from a series of rigorous experiments to elucidate CXCR7's essential role in the progression a...
Jul 24, 2007
Mountain View, CA - July 24, 2007 - ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, today announced that it has earned a $5 million milestone payment from GlaxoSmithKline (NYSE: GSK) for progress in its sma...
May 23, 2007
Mountain View, CA - May 23, 2007 — ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, presented data today from the company's Phase 2 clinical trial of Traficet-EN™ (CCX282-B), an orally...
Page: FirstPrevious ...
18
NextLast
= add release to Briefcase